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Abstract 
 
The parathyroid glands play an overall regulatory role in the systemic calcium 
(Ca
2+
) homeostasis. The purpose of the present study was to demonstrate the 
presence of the Ca
2+
 channels transient receptor potential vanilloid (TRPV) 5 
and TRPV6 in human parathyroid glands. Reverse-transcriptase PCR was 
carried-out to evaluate the presence of TRPV5 and TRPV6 mRNAs in sporadic 
parathyroid adenomas and normal parathyroid glands. Western blot and 
immunocytochemical assays were used to assess protein expression, cellular 
localization and time expression in primary cultures from human parathyroid 
adenoma. TRPV5 and TRPV6 transcripts were then identified both in normal 
and pathological tissues. A predominant immunoreactive band was detected at 
80-85 kDa for both vanilloid channels which appeared significantly reduced 
after peptide:N-glycosidase F (PNGaseF) treatment. These channels co-
localized with the calcium sensing receptor (CASR) on the membrane surface, 
but immunoreactivity was also detected in the cytosol and around the nuclei. 
Our data showed that western blotting recorded an increase of protein 
expression of both channels in adenoma samples compared with normal glands 
suggesting a potential relation with the cell calcium signaling pathway and the 
pathological processes of these glands.  
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INTRODUCTION 
  
Parathyroid Glands 
The parathyroid glands are small glands of the endocrine system which are 
located in the neck behind the thyroid. Parathyroid glands control the 
homoeostasis of  Ca
2+
 in our bodies. Usually we have 4 parathyroid glands 
which  have normally the size of a grain of rice. Occasionally they can be as 
large as a pea and still be normal. These glands control the level of calcium in 
the blood  by producing the parathyroid hormone (PTH). Calcium is the most 
important element in our bodies: it is important, not only for bones and teeth, 
but also for nerve functioning, muscle contractions, blood clotting and 
glandular secretion. If we don't have enough calcium for these functions, the 
body will take it from the bones, causing them to weaken and increasing the 
risk of fracture (osteoporoses) . Calcium deficiency  may also cause twitching, 
spasms, convulsions and even death, while too much calcium can lead to a 
weakening of muscle tone and kidney stones. 
 
Structure of Parathyroid Glands 
The parathyroid parenchyma consists of epithelial cords surrounded by a dense 
network of sinusoids. The epithelial cords may occur in compact form, lattice 
or even lobular, and consist of the following cell types:  
 parathyroid principal cells (chief cells) : very numerous, small and dark cells 
that produce PTH .  
 oxyphil cells: more bigger and clear than the principal cells. these cells appear 
at the onset of puberty, but have no known function (fig. 1). 
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Fig. 1. Chief and Oxyphil Cells 
 
 Parathyroid Hormone 
PTH and the biologically active form of vitamin D are the main calciotropic 
hormones controlling Ca
2+
 balance [1,2, 3]. 
The parathyroid gland plays a key role through the capacity to sense minute 
changes in the extracellular Ca
2+
 concentration. Upon a decrease in the 
extracellular Ca
2+
 level, PTH is secreted into the circulation, and then acts 
primarily on the kidney and bone, where it activates the PTH/PTHrP receptor 
[3].  
Early studies using micropuncture and cell preparations demonstrated that PTH 
directly stimulates active Ca
2+
 reabsorption in the distal part of the nephron [4, 
5]. In addition to enhancing tubular Ca2+ reabsorption, PTH stimulates the 
activity of 25-hydroxyvitamin-D3-1a-hydroxylase (1a-OHase), a crucial 
enzyme in the biosynthesis of 1,25- (OH)2D3 and, thereby, increases the 1,25-
(OH)2D3- dependent absorption of Ca
2+
  in the small intestine [6].     
 7 
 
Hyperparathyroidism   
In hyperparathyroidism, in the absence of a known stimulus, one or more of the 
four parathyroid glands secrete excess PTH, resulting in hypercalcaemia. 
Single gland adenoma is the most common cause (75–85%) [8].     
The precise cause of primary hyperparathyroidism is unknown, but ionising 
radiation is a possible association [9]. Primary hyperparathyroidism is a 
common endocrine disorder characterized by elevated PTH levels that are 
inappropriate to the level of serum Ca
2+
 [10].  This underlines the importance 
of PTH as an essential component of Ca
2+
 homeostasis. Secretion of PTH from 
the parathyroid glands is regulated by the ambient Ca
2+
 concentration, sensed 
by the parathyroid Ca
2+
 sensing receptor (CaSR) [11]. The CaSR is activated 
by high serum Ca
2+
 concentrations and coupled to the inhibition of  PTH 
secretion.  Inactivating  mutations of the CaSR result in familial hypocalciuric 
hypercalcemia or neonatal severe hyperparathyroidism [12]. Whereas 
autosomal dominant hypocalcemia is caused by activating mutations [13].    
These disorders demonstrate the predominant role of the CaSR in controlling 
parathyroid gland function and, hence, the role of PTH in regulating systemic 
Ca
2+
 balance. From the clinical symptoms of these PTH-related disorders, like 
hypo- or hypercalciuria and renal stone formation, it is clear that also renal 
Ca
2+
 handling is affected. Regulation of Ca2+ reabsorption in the kidney is 
crucial for the maintenance of normal serum Ca
2+
 levels and occurs via 
paracellular as well as transcellular routes. Transcellular or active Ca
2+
 
reabsorption is the primary target for regulation by calciotropic hormones, 
including 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and PTH. Active Ca
2+
 
reabsorption takes place in the distal convoluted tubule (DCT) and connecting 
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tubule (CNT) of the kidney. Luminal Ca
2+
 enters these tubular cells via the 
epithelial Ca
2+
 channels, TRPV5 and TRPV6, is then transported across the 
cell in association with Ca
2+
 -carrier proteins (i.e. calbindins) and it is finally 
extruded into the blood stream via the Na
+
/ Ca
2+
- exchanger (NCX1) and the 
plasma membrane Ca
2+
 - ATPase (PMCA1b) [14].  PTH receptors have been 
detected throughout the kidney, as well as in the actively Ca
2+
 transporting 
tubules DCT and CNT [15-16].  Therefore, the contribution of these Ca
2+
 
transport proteins to the altered Ca
2+
 handling in PTH related disorders seems 
likely. 
Treatment of primary hyperparathyroidism has been limited to surgical 
ablation (parathyroidectomy) of the affected glands. A new approach for 
treating primary hyperparathyroidism is to target the mechanisms that regulate 
the secretion of PTH. 
The CaSR is the first step in this process. In the last decade synthetic 
compounds, referred to as calcimimetic compounds, have been developed [17-
18].  
Type I calcimimetics are full agonists of the CaSR, whereas type II 
calcimimetics are small organic compounds that, upon binding to the receptor, 
enhance the sensitivity of the CaSR to Ca
2+
 in an allosteric fashion, thereby 
altering PTH secretion by the parathyroid glands.  In this way, the type II 
calcimimetic compounds may provide a novel therapy for treating 
hyperparathyroidism [17,18]. 
 
  Parathyroid Adenoma 
A parathyroid adenoma is a benign tumor of the parathyroid gland. It generally 
causes hyperparathyroidism. The cause of most parathyroid adenomas is 
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unknown. However, about 10% are thought to be hereditary [19] . Radiation 
exposure of the head and neck also may increase the risk of adenomas. 
Adenomas induce the parathyroid gland to produce more PTH than the body 
needs, a condition that led to primary hyperparathyroidism. Too much PTH 
upsets the body’s normal calcium balance, which increases the amount of 
calcium in the blood stream. A similar but less common condition, called 
secondary hyperparathyroidism, can occur in people with chronic kidney 
failure.  
Surgery is the only cure for parathyroid adenomas. 
 
 Paratyroid Carcinoma 
Parathyroid carcinoma is a rare malignant neoplasm resulting in parathyroid 
adenoma to carcinoma progression. It forms in tissues one or more of 
the parathyroid glands and it is so rare and can led to hyperparathyrodismo. 
 
Transient Receptor Potential (TRP)  Channels 
Transient receptor potential  (TRP)  cation channels mediate the flux of Na
+
  
and Ca
2+
 across the plasma membrane and into the cytoplasma [20]. TRP 
channels were first discovered due to a mutation in the Drosophila 
photoreceptor, which resulted in  inhibited Ca
2+
 permeability and sensitivity to 
light [21]. The influx of cations into the cytoplasm depolarizes cells and is 
necessary for action potentials in excitable cells such as neurons [22]. In 
nonexcitable cells, membrane depolarization by TRP channels stimulates 
voltage-dependent channels (Ca
2+
 , K
+
, Cl
-
) and influences many cellular 
events, such as transcription, translation, contraction, and migration [23]. RP 
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channels and their regulation are fundamentally important in cellular function 
and disease [20]. 
 
 TRP Gene Expression 
TRP genes are expressed in organisms from archaea to plants to animals [24].  
In animals, TRP is expressed in brain, heart, lung, and other tissues. 
Mammalian TRP channels possess a high degree of sequence homology, 
particularly in the putative functional regions [25]. The TRP superfamily of 
genes is categorized into two groups based on sequence and topological 
similarities: 
Group 1 includes TRPC, TRPV, TRPM, TRPA, and TRPN.  
Group 2 includes TRPP and TRPML (fig. 2a) [25]. 
 
TRP Channel Function 
TRP proteins form cation channels with varying selectivity to different cations 
[26]. TRP proteins are transmembrane proteins with six transmembrane 
domains with a pore domain wedged between the fifth and sixth 
transmembrane domains (fig. 2b). The N- and C-terminal domains are 
intracellular and believed to be involved in regulation of TRP channel function 
and in channel assembly.  
It is believed that TRP channels are homo- or heterotetramers of TRP proteins, 
with each subunit contributing to selectivity of the ion-conducting pore (fig. 
2c) [27]. Allosteric interactions between subunits are thought to contribute to 
gating of TRP channels; however, the location and structure of these gates are 
unknown. Amino acid sequences flanking the pore-forming regions of TRP 
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proteins are strongly conserved across the various TRP channel families, 
highlighting their importance in pore formation or pore gating [28].  
 
                      TRP Channel Regulation 
                     TRP channel function is regulated by [29] : 
 plasma membrane receptor activation, 
 ligand activation,  
 direct activation 
 indirect activation  
G protein coupled receptors (GPCRs) and receptor tyrosine kinase act through 
diacylglycerol (DAG) to activate TRP channels on the plasma membrane 
[30,31]. These channels are termed receptor-operated channels. Furthermore, 
stimulation of these receptors depletes intracellular endoplasmic 
reticulum/sarcoplasmic reticulum (ER/SR) Ca
2+
 stores and leads to store-
operated Ca
2+
 entry through TRP channels on the plasma membrane. Various 
ligands can activate TRP channels. Ligand activation includes activation by 
exogenous small molecules such as capsaicin, icilin, 2-Aminoethoxydiphenyl 
Borate, endogenous lipids such as DAG, phosphoinosidides, eicosanoids, 
purine nucleotides, ions such as Ca
2+
 , and Mg
2+
, and the Ca
2+
 / Calmodulin 
complex [32–34].  
TRP channel activity can be stimulated through direct activation. Examples of 
direct activation of TRP channels include temperature change, [35] mechanical 
stimulation, [36] and conformational coupling with other proteins such as 
STIM1 (stromal interacting molecule) or IP3R (inositol 1,4,5-trisphosphate 
receptor). Indirect activation refers to transcriptional control or insertion of 
vesicles containing TRP proteins into the plasma membrane. 
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Fig.2  Classification and structure of TRP channels. (a) Phylogenic tree of the 
seven known families of TRP proteins. The original TRP protein identified in 
Drosophila melanogaster is most closely related to TRP channels. (b) Two-
dimensional representation of TRP channel structure. Six transmembrane 
domains (TM1-TM6), ankyrin repeats, pore region, and TRP box are shown and 
described further in the text.  (c) Subunit arrangement of TRP monomers into 
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functional homo- or heterotetrameric channels with a central ion-conducting 
pore. (d) Schematic representation of key regulatory sites for the TRPC4 protein. 
 
 
TRPV Channels 
TRPV channels are subdivided into two groups composed of TRPV1–4 and 
TRPV5 and 6 (fig. 2a) [37].  
 
TRPV1 
TRPV1 forms vanilloid receptor and noxious thermosensor cation channels 
that are outwardly rectifying in humans and mice.[38] Capsaicin-activated 
TRPV1 channels have roughly a 10:1 selectivity of Ca
2+
  over Na
+
, with 
selectivity of Ca
2+
  > Mg
2+
 > Na
+
 = K
+
 = Cs [39]. Heat-activated TRPV1 
channels have a 4:1 selectivity of Ca
2+
  over Na
+
 [40]. TRPV1 is inactivated by 
phosphorylation by cyclic adenosine monophosphate (cAMP)-dependant 
protein kinase and pharmacologically by capsazepine, ruthenium red, 
iodoresiniferatoxin, (N-(4-tertiarybutylphenyl)-4-(3-cholorphyridin- 2-
yl)tetrahydropryazine-1(2H)-carbox-amide) (BCTC), and Phosphatidylinositol 
4, 5-Bisphosphate (PIP2). TRPV1 channels are activated by capsaicin (EC50 = 
0.7 mM), resiniferatoxin (EC50 = 40 nM), anandamide, heat (threshold of 
43°C), extracellular protons, and ethanol 
[41]. 
TRPV1 is expressed in trigeminal and dorsal root ganglia, brain, and spinal 
cord. TRPV1 channels function physiologically in nociception, inflammation, 
temperature sensation, and capsaicin detection [42]. 
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TRPV2  
TRPV2 channels constitute an outwardly rectifying nonselective cation current 
with roughly 3:1 selectivity for Ca
2+
  over Na
+
. TRPV2 channels are insensitive 
to capsaicin and activated by heat, with a threshold of 52°C. TRPV2 channels 
can be inhibited by ruthenium red.  
TRPV2 is expressed in dorsal root ganglion neurons, brain, spinal cord, spleen, 
lung, vascular myocytes, and vascular smooth muscle. It seems to have a role 
as a noxious heat thermosensor channel [43]. 
 
TRPV3  
TRPV3 forms outwardly rectifying cation channels with roughly 10:1 
selectivity of Ca
2+
  over Na
+
. TRPV3 channels are activated by temperature at 
roughly 35°C and are believed to mediate sensation of warmth in skin. TRPV3 
is inactivated by cooling and blocked by ruthenium red [44]. 
 
TRPV4 
TRPV4 forms outwardly rectifying cation channels with roughly 6:1 selectivity 
of Ca
2+
  over Na
+
 [45]. TRPV4 channels function as osmosensor channels, 
which mediate sensitivity to pressure and acidic nociception in nerve cells. 
TRPV4 is activated by reduction in osmolarity, phorbol esters, arachidonic 
acid, and stretch [46]. TRPV4 is inactivated by the Ca/CaM complex and 
blocked by ruthenium red, gadolinium, and lanthanum. TRPV4 is expressed in 
brain, liver, kidney, fat, heart, testis, salivary gland, and trachea [47]. 
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TRPV5 and TRPV6  
TRPV5 and TRPV6 possess unique properties that distinguish them from other 
TRP channels [48,49]. Compared with TRPV1-V4, TRPV5 and its highly 
homologous TRPV6 are only distantly related, as evident from the phylogenic 
tree depicted in (Fig 3a). TRPV5 and TRPV6 share 75% homology at the 
amino acid level. The main sequence differences are located in the N- and C-
terminal tails. However TRPV5 and TRPV6 reveal only 30–40% homology 
with other members of the TRP family, and possess unique properties that 
distinguish them from other TRP channels. 
First, these channels have a constitutively activated Ca
2+
 permeability at 
physiological membrane potentials [50-52]. This contrasts with other members 
of the TRP family which are activated by receptor stimulation, diacylglycerol 
and inositol 1,4,5-trisphosphate (TRPCs), ligands, heat, protein kinase C 
(PKC), growth factors and phorbol derivatives (TRPVs), and by cold, menthol 
and adenosine. 
Second, TRPV5 and TRPV6 retain a Ca
2+
 over Na
+
 selectivity that is much 
larger (PCa/PNa > 100) than observed for any other member of the TRP 
superfamily (PCa/PNa ≤ 9) [50-52]. 
 
TRPV5 and TRPV6 Molecular Structure  
The structure of TRPV5 and TRPV6 shows typical topology features shared by 
all members of the TRP family, including six transmembrane regions, a short 
hydrophobic stretch between transmembrane segment 5 and 6, which is 
predicted to form the Ca
2+
 pore, and large intracellular N- and C-terminal 
domains (Fig. 3) [53]. 
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Fig. 3. The predicted topology of the TRPV5/6 monomer and architecture of the 
TRPV5/6 (hetero)tetrameric channel complex. (A) Schematic representation of 
TRPV5 and TRPV6 topology. Transmembrane segments are numbered, the pore 
region is depicted in grey, and ankyrin repeats in the N-terminal tail are indicated 
with A. (B) Top view of the TRPV5/6 (hetero)tetrameric channel. Four monomeric 
TRPV5/6 subunits form a tetrameric complex consequently four aspartate 
residues (D542) form the Ca
2+-
binding site within the pore of the channel. 
 
 
These intracellular regions contain several conserved putative regulatory sites 
that might be involved in regulation of channel activity and trafficking. 
The characteristic pore region of TRPV5 and TRPV6 is unique for its high 
Ca
2+
 selectivity [54,55]. A single aspartic residue in the pore region at position 
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number 542 (D542) is crucial for Ca
2+
 permeation. This amino acid is 
completely conserved in TRPV6. Mutation of D542 into an alanine abolishes 
Ca
2+
 permeation, but does not affect the permeation of monovalent cations 
[55].  Both channels contain a conserved N-glycosylation site in the 
extracellular loop between transmembrane region 1 and 2. A recent study on 
the glycosylation state of TRPV5 and TRPV6, expressed 
in Xenopus laevis oocytes, indicated that these channels are not only translated 
as a core protein, but are also post-translationally modified resulting in higher 
molecular weight proteins of 85–100 kDa [56]. Glycosylated TRPV5 and 
TRPV6 proteins are reduced after incubation with endoglycosidase H, which 
cleaves high mannose type sugars, and completely disappear after treatment 
with N-glycosidase F, which removes all types of sugars. This observation 
indicates that both epithelial channels are high mannose- and complex-
glycosylated [56]. 
 N-Glycosylation sites have been shown to play an important role in protein 
folding, intracellular trafficking and channel activity [57]. The N-terminal 
domain of TRPV5 and TRPV6 contains three ankyrin repeats. This structural 
element is present in several proteins and plays a role in protein–protein 
interactions [58].  
Ankyrin repeats can interconnect integral membrane proteins such as ion 
channels with the spectrin–actin-based membrane skeleton [59]. Thus, TRPV5 
and TRPV6 may be linked to the cytoskeleton via its ankyrin repeats, enabling 
anchorage to the plasma membrane and channel regulation via actin filaments. 
The N- and C-terminal tails of TRPV5 and TRPV6 each contain an internal 
PDZ motif which can function as part of a molecular scaffold via interaction 
with PDZ-domain containing proteins. Via this interaction, transporters, ion 
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channels and receptors are coupled to intracellular signal in  molecules, which 
regulate their activity, and position them to specialized regions in a cell [60,61] 
.  
Besides this, PDZ motifs have been implicated in the oligomerization of ion 
channels. This has been shown for the light-sensitive ion channel, TRP, which 
interacts with the PDZ domain containing protein INAD (fig. 4) [62].  
 
 
 
 
 
Fig.4. Potential regulatory sites are indicated in the N- and C- tail of TRPV5 and 
TRPV6, including ankyrin repeats, PDZ motifs and conserved PKC 
phosphorylation sites. 
 
TRPV5 and TRPV6 possess several potential phosphorylation sites for PKC, 
cAMP- and cGMP-dependent protein kinase (PKA and cGK) and Ca
2+
 
/calmodulin-dependent protein kinase II (CaMKII) in their N- and C-terminal 
tails. Many of these putative phosphorylation sites are conserved among 
species, which might point to an important role in TRPV5 and TRPV6 
function. However, the contribution of these regulatory sites to modulation of 
TRPV5 and TRPV6 remains to be established. It was proposed that this repeat 
initiates a molecular zippering process that proceeds past the fifth ankyrin 
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repeat and creates an intracellular anchor that is necessary for functional 
subunit assembly. In addition, the N-tail and to a lesser extent the C-tail are 
critical for channel assembly of TRPV5 and the assembly domain in the N-tail 
of TRPV5 overlapped with the first ankyrin repeat (fig. 4) [56]. 
 
 TRPV5 and TRPV6 Pharmacology  
TRPV5 and TRPV6 channels are constitutively active when inserted into the 
plasma membrane. Regulation most probably occurs by variation of the 
channel density on the plasma membrane. Expression of TRPV5 is influenced 
by 1,25-dihydroxy vitamine D3 [63], the Ca
2+
 and annexin II [64]. Calmodulin 
binds to both TRPV5 and TRPV6 in a Ca
2+
- dependent fashion and supports, at 
least, the activation of TRPV6. Extracellular alkalization causes TRPV5 
accumulation in subplasmalemmal vesicles. From this pool, TRPV5 can be 
rapidly recruited into the plasma membrane. An important regulatory pathway 
comprises the tissue serine protease kallikrein, Kallikrein activates the 
bradykinin receptor- 2, which in turn activates PKC dependently on 
diacylglycerol via PLC. Phosphorylation of TRPV5 increases membrane 
insertion of the channel and delays retrieval [65]. The PKC activator 1-oleoyl-
acetyl-sn-glycerol (OAG) also increased TRPV5 surface abundance. The 
OAG-mediated increase of TRPV5 was prevented by preincubation with 
specific PKC inhibitors. Knockdown of caveolin-1 also prevented the increase 
of TRPV5 by OAG. PTH  increased TRPV5 current density in cells 
coexpressing TRPV5 and type 1 PTH receptor. The increase caused by PTH 
was prevented by PKC inhibitor, mutation of Ser299/Ser654, or knockdown of 
caveolin-1. This mechanism of regulation by PKC may contribute to the short-
term stimulation of TRPV5 and renal Ca
2+
 reabsorption by PTH [66].  
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TRPV5 is highly regulated by WNK4, a protein serine/ threonine kinase whose 
gene mutations cause familial hyperkalemic hypertension. Expression of 
WNK4 increases surface expression of TRPV5 and therefore modulates 
calcium reabsorption mediated by this channel [67].  
The pro-urine hormone klotho can stimulate TRPV5 and TRPV6 by N-
oligosaccharide hydrolysis. Klotho is a -glucuronidase that hydrolyzes 
extracellular sugar residues on TRPV5, entrapping the channel in the plasma 
membrane. Klotho effects are primarily restricted to the epithelial Ca2 
channels TRPV5 and TRPV6 [68,69]. The antifungal azole econazole is the 
most effective inhibitors of currents through TRPV5 described, with IC50 
values between 0.1 and 1µM. The divalent cation current block profile for 
TRPV5 is Pb
2+
 > Cu
2+
 = Zn
2+
 = Co2 = Fe
2+
, with IC50 values between 1 and 
approximately 10 µM [70].  
TRPV6 can be blocked by RR but has a 100-fold lower affinity for RR (IC50 9 
nM) than TRPV5. Ca
2+
-induced inactivation occurs at hyperpolarized 
potentials in the presence of extracellular Ca
2+
. Half-maximal inactivation by 
[Ca
2+
]i occurs at a concentration of ~100 nM. TRPV6 is Ca
2+
 -dependently 
inactivated, a process triggered by Ca
2+
 dependent  PLC activation and 
depletion of PIP2.  
Edelfosine induce sustained TRPV6 activation in a duodenal sac assay. Thus, 
PLC modulators can be used as novel TRPV6 Ca
2+
 reabsorption modulators 
[71]. Blockade of TRPV5 and TRPV6 by extracellular Mg
2+
 is voltage-
dependent and critically depends on a single aspartate residue in the selectivity 
filter of the TRPV5/6 pore. Intracellular Mg
2+
 also exerts a voltage-dependent 
block that is alleviated by hyperpolarization and contributes to the time-
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dependent activation and deactivation of TRPV6-mediated monovalent cation 
currents [72]. 
TRPV6 interacts with the protein tyrosine phosphatase and is probably 
inhibited by Ca
2+
 via an intermediate reactive oxygen species. Inhibition of 
tyrosine dephosphorylation by protein tyrosine phosphatase inhibition causes a 
maintained Ca
2+
 influx via TRPV6, thus inducing a positive feedback [73]. 
 Expression of TRPV5 and TRPV6  
The tissue distribution of TRPV5 and TRPV6 has been studied extensively by 
Northern blot, RT-PCR analysis and immunohistochemistry.  
Both channels are expressed in organs, in which exchange of Ca
2+
 occurs 
across epithelia and are involved in the maintenance of body Ca
2+
 balance, 
including the kidney, gastrointestinal tract and bone (Table 1). 
 
 
Tab.1. Tissue expression of TRPV5 and TRPV6 
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TRPV5 and TRPV6 can also be found in exocrine tissues such as pancreas, 
prostate, mammary gland, sweat gland and salivary gland [74].  Epithelial 
calcium channels present in placenta might be involved in placental transfer of 
maternal Ca
2+
. This is a crucial process in fetal development, which is carried 
out by the placental syncytiotrophoblast layer. The finding that mRNA of 
TRPV5 and TRPV6 is expressed in this layer might indicate that these Ca
2+
 
channels account for the basal Ca
2+
 uptake by these cells [75,76].  The relative 
mRNA level of TRPV5 and TRPV6 in tissues co-expressing these channels is 
different: in duodenum, the TRPV5 mRNA level is much lower than that of 
TRPV6 mRNA [77].  
The variation in TRPV5 and TRPV6 expression patterns found in different 
studies in intestine, kidney, testis, oesophagus, ileum and colon could have 
resulted from differences between species, or expression below detection levels 
of TRPV5 or TRPV6 in these tissues. In general TRPV5 seems to be the major 
isoform in kidney, whereas TRPV6 is highly expressed in small intestine, 
although both isoforms are co-expressed in these tissues. In kidney, TRPV5 is 
localized in the apical domain of the epithelial cells lining the late part of the 
distal convoluted tubule (DCT2), while along the connecting tubule (CNT) the 
expression level decreases, and becomes more cytoplasmic [78–80]. In these 
nephron segments TRPV5 co-localizes with other proteins that are involved in 
Ca
2+
 transport such as calbindin-D28K, Na
+–Ca2+ exchanger type 1 and plasma 
membrane Ca
2+ 
-ATPase 1b [81]. In pancreas, TRPV5 is present in secretory 
granules of the cells where it co-localizes with calbindin-D28K and insulin 
[82]. This suggests a role for TRPV5 in insulin secretion, although such a 
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function could not be confirmed in Zucker diabetic fatty (ZDF) rats, an animal 
model for type 2 diabetes mellitus.  
In contrast to TRPV5, TRPV6 mRNA is found in the exocrine acinar cell of 
the pancreas, but not in pancreatic duct cells  and  β cells [83]. 
TRPV6 protein expression, in the mouse and human gastrointestinal tract, is 
essentially restricted to the epithelial cells, and is largely confined to the apical 
cell surface [83]. As this is the major site for Ca
2+
 absorption, TRPV5 and 
TRPV6 expression patterns are in line with the role of these proteins in dietary 
Ca
2+
 uptake [83,84]. 
 
Role of TRPV5 and TRPV6 in Ca
2+ 
Uptake 
Ca
2+
 play a fundamental role in many cellular processes and its extracellular 
concentration is kept under strict control by the concerted actions of kidney, 
intestine and bone to allow proper physiological functions. The first step in 
active, transcellular Ca
2+
 transport is the influx of Ca
2+
 across the apical plasma 
membrane. Inside the cell, Ca
2+
 is bound to specialized proteins, called 
calbindins, to maintain low intracellular Ca
2+
 concentrations. Bound Ca
2+
 
subsequently diffuses to the basolateral side of the cell, where it is extruded 
into the bloodstream via the Na
+
/ Ca
2+
-exchanger (NCX1) and/or Ca
2+
 -
ATPase (PMCA1b). The epithelial Ca
2+
 channels TRPV5 and TRPV6  
constitute the apical Ca
2+
 entry mechanism in active Ca
2+
 transport in kidney 
and intestine (fig.5).  
The central role of TRPV5 and TRPV6 in active Ca
2+
 (re)absorption makes it a 
prime target for regulation to maintain Ca
2+
 balance [85, 86, 87]. 
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Fig. 5.  Integrated model of active epithelial Ca
2+
 transport. Ca
2+
 enters the cell 
from the luminal side via TRPV5 and/or TRPV6, subsequently binds to calbindin-
D28K, and is extruded at the basolateral membrane by a Na
+
/ Ca
2+
 exchanger 
(NCX1) and/or a plasma membrane Ca
2+
 ATPase (PMCA1b). In this way, there is 
net Ca
2+
 (re)absorption from the luminal space to the extracellular compartment. 
Ca
2+
 (re)absorption is fine-tuned by calciotropic hormones. The active form of 
vitamin D [1,25(OH)2D3] stimulates the individual steps of transcellular Ca
2+
 
transport by increasing the expression level of TRPV5/6, calbindins, and the 
extrusion systems. 
 
 Regulation of TRPV5 and TRPV6  
TRPV5 and TRPV6, are specialized epithelial Ca
2+
 channels responsible for 
the critical Ca
2+
 entry step in transcellular Ca
2+
 (re)absorption in intestine and 
kidney, respectively. A tight control of the amount of Ca2+ influx across the 
plasma membrane is important in many physiological processes. A delicate 
regulation of the expression and activity of TRPV5 and TRPV6 is, therefore, of 
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utmost importance to maintain the extracellular Ca
2+
 balance. This regulation 
occurs at different levels, including: 
1. transcriptional and translational regulation,  
2. the tetrametric channel stoichiometry,  
3.  trafficking of channels to and from the plasma membrane and  
4.  modulation of channel activity at the plasma membrane (fig. 6). 
 
                              
 
Fig. 6. Levels at which TRPV5 and TRPV6 are regulated. Regulation of 
epithelial Ca2+ channels can, hypothetically, occur at the level of (1) 
transcription and translation, (2) the tetrameric channel stoichiometry, (3) 
intracellular trafficking of channels to the plasma membrane and (4) 
regulation of channel activity at the plasma membrane 
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Parathyroid Hormone (PTH) 
PTH  and the biologically active form of vitamin D [1,25-(OH)2D3] are the 
main calciotropic hormones controlling Ca
2+
 balance [1,2].   
The parathyroid gland plays a key role through the capacity to sense minute 
changes in the extracellular Ca
2+
 concentration. Upon a decrease in the 
extracellular Ca
2+
 level, PTH is secreted into the circulation, and then acts 
primarily on the kidney and bone, where it activates the PTH/PTHrP receptor 
[3]. Early studies using micropuncture and cell preparations demonstrated that 
PTH directly stimulates active Ca
2+
 reabsorption in the distal part of the 
nephron [4,5].  In addition to enhancing tubular Ca
2+
 reabsorption, PTH 
stimulates the activity of 25-hydroxyvitamin-D3-1a-hydroxylase (1a-OHase), a 
crucial enzyme in the biosynthesis of  1,25-(OH)2D3 and, thereby, increases the 
1,25-(OH)2D3- dependent absorption of Ca
2+
 in the small intestine [7]. It was 
demonstrated in other studies that parathyroidectomy in rats results in 
decreased serum PTH levels and hypocalcaemia, which was accompanied by 
decreased TRPV5 mRNA levels and protein abundance [88]. Supplementation 
with PTH restored serum Ca
2+
 concentrations and TRPV5 abundance in 
kidney, suggesting that PTH affects renal Ca
2+
 handling through the regulation 
of TRPV5. 
 
 
  Vitamin D 
The active metabolite of Vitamin D, 1,25(OH)2D3, is an important regulator of 
the body Ca
2+
 homeostasis. 1,25(OH)2D3 has been shown to enhance the 
absorption of dietary Ca
2+
 in the small intestine and to increase Ca
2+
 
reabsorption in the distal nephron [89,90]. As TRPV5 and TRPV6 fulfill an 
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important role in Ca
2+
 (re)absorption, regulation of these channels by 
1,25(OH)2D3 has been investigated 
using different Vitamin D deficiency models . 
It was demonstrated that in kidney of 25-hydroxyvitamin D3-1-α-hydroxylase 
(1α-OHase) knockout mice, which are unable to synthesize 1,25(OH)2D3, 
Vitamin D-deficient rats and in mice with a mutant Vitamin D receptor (VDR), 
the basal TRPV5 mRNA and protein level was decreased as compared with 
wildtype mice [91,92]. Supplementation of these animals with 1,25(OH)2D3 
increased the renal TRPV5 expression to normal values measured for wild type 
mice. A similar regulation was found for TRPV6 in duodenum [93]. The 
increase in TRPV5 and TRPV6 mRNA expression, observed in these studies, 
suggests that the transcription of TRPV5 and TRPV6 is controlled by 
1,25(OH)2D3. This is supported by the finding that the putative human and 
murine TRPV5 promoter contains four predicted Vitamin D-responsive 
elements (VDRE) [91]. 
 Thus, activation of the TRPV5 promoter by 1,25(OH)2D3 can account for the 
increased expression levels of TRPV5 and normalization of the serum Ca
2+
 
level in mouse and rat Vitamin D deficiency models. Together these findings 
indicate that the expression of TRPV5 and TRPV6 is indeed controlled by 
1,25(OH)2D3. 
 
Estrogen 
Estrogen is involved in bone mineralization and its deficiency in 
postmenopausal women results in bone loss because of a negative Ca
2+
 
balance. In ovariectomized 1α-OHase knockout mice 17 β-estradiol 
replacement therapy resulted in upregulation of renal TRPV5 mRNA and 
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protein levels, leading to normalization of plasma Ca
2+
 levels [94]. Thus, 
TRPV5 expression is independent of Vitamin D, transcriptionally controlled by 
estrogen. Recent findings indicate that also TRPV6 expression is regulated by 
estrogen, as duodenal expression of TRPV6 mRNA of male 1α-OHase 
knockout mice and ovariectomized rats is upregulated after 17-β-estradiol 
administration. These data indicate that the function of estrogen in maintenance 
of the Ca
2+
 balance might be at least in part fulfilled by regulation of TRPV5 
and TRPV6 levels, thereby controlling (re)absorption of the amount of Ca
2+
 
that is needed for bone calcification. However the mechanism of estrogen-
controlled upregulation of epithelial calcium channel mRNA remains to be 
elucidated, since estrogen responsive elements are not consequently present in 
the putative TRPV5/6 promoter region [95]. 
 
Dietary Ca
2+ 
In addition to the calciotropic hormones, there are
 
indications that Ca
2+
 itself 
can affect TRPV5/6 expression. In mice with a mutant nonfunctioning Vitamin 
D receptor, dietary Ca
2+
 levels regulated the expression of TRPV5 and TRPV6 
in kidney and duodenum, respectively [95]. This indicates that Ca
2+
 can exert a 
regulatory effect on TRPV5/6 expression independent of 1,25(OH)2D3. This 
finding was supported by another study in which feeding of 1α-OHase 
knockout mice a Ca
2+
-enriched diet resulted in induction of TRPV5 expression 
and normalization of the serum Ca2+ level [92]. Taken together, these studies 
indicate that dietary Ca
2+
 intake can directly modulate the expression levels of 
TRPV5 and TRPV6. The physiological mechanism whereby plasma Ca
2+
 acts 
via a negative feedback mechanism, eventually leading to the suppression of 
1α-OHase activity, which decreases expression of Ca2+ transport proteins and 
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Ca
2+
 reabsorption. Similarly, dietary rescue of the hypocalcemic state in VDR
-/-
 
mice up-regulated the significantly decreased duodenal TRPV6 mRNA 
expression, whereas in wild-type mice high dietary Ca
2+
 content decreased 
TRPV6 expression due to a decrease of serum 1,25-(OH)2D3 [96].  
Thus, Ca
2+
 supplementation can up-regulate TRPV5/6 gene transcription in the 
absence of circulating 1,25- (OH)2D3.  
 
 
TRPV5/6 Trafficking to the Plasma Membrane: S100A10-Annexin 2 
Complex  
Accurate trafficking of channels and transporters to the plasma membrane is 
essential for transcellular ion transport. Van der Graf gave the first evidence of 
a regulatory role for the S100A10-annexin 2 heterotetramer in the trafficking 
of TRPV5 and TRPV6 [97]. S100A10, a 97-amino acid protein member of the 
S100 superfamily, was identified as an associated protein of TRPV5 and 
TRPV6 using the yeast two-hybrid technique. S100A10 is found tightly 
associated with annexin 2, a member of the Ca
2+
 and phospholipids-binding 
proteins which is implicated in numerous biological processes including 
exocytosis, endocytosis and membrane- cytoskeleton interactions [98]. The 
association of S100A10 with TRPV5 and TRPV6 was restricted to a short 
conserved peptide sequence located in the C-tail of these channels. The first 
threonine of this sequence was identified as a crucial amino acid for binding 
and channel function. When this particular threonine was mutated, the activity 
of TRPV5 and TRPV6 was abolished accompanied by a major disturbance in 
their subcellular localization. This indicated that the S100A10-annexin 2 
heterotetramer facilitates the translocation 
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of TRPV5 and TRPV6 channels towards the plasma membrane. The 
importance of annexin 2 in this process was demonstrated by showing that 
small interfering RNA-based down-regulation of annexin 2 significantly 
inhibits TRPV5 and TRPV6 currents. The latter demonstrated that annexin 2 in 
conjunction with S100A10 is crucial for TRPV5 and TRPV6 activity. 
Interestingly, S100A10 as well as annexin 2 appear to be regulated by 1,25-
(OH)2D3, further supporting the importance of the S100A10-annexin-2 
complex in the regulation of 1,25-(OH)2D3-dependent TRPV5/6-mediated Ca
2+
 
influx [97, 99] (fig.7). 
 
 
 
 
Fig.7. Predicted topology of TRPV5/6 including the various binding sites 
identified for each associated protein. The extracellular loop between 
transmembrane domain (TM) 1 and TM2 is glycosylated. In the COOH 
 31 
terminus, Rab11, 80K-H, and S100A10 bind within a _30-amino acid-
containing helical stretch juxtaposed to TM6. The S100A10-annexin 2 (Anx2) 
complex interacts with a conserved region within this stretch containing the 
VATTV amino acid sequence, whereas Rab11a and 80K-H share a binding site 
COOH terminally flanking this sequence. Na_/H_ exchanger regulatory factor 
2 (NHERF2) specifically interacts with TRPV5 at the extreme COOH terminus 
of this channel. Calmodulin (CaM) has multiple binding sites present in the 
NH2 terminus, COOH terminus, and transmembrane region. The region 
between TM2 and TM3 of TRPV6 (indicated by vertical lines) is functionally 
linked to the fast Ca2_-dependent inactivation of this channel, suggesting the 
binding of an unidentified protein to this region. 
 
 
 
                       Regulation of TRPV5/6 by Channel-Associated Proteins  
 
 Calmodulin.  
Calmodulin (CaM) is a ubiquitous protein, well known to be involved in Ca
2+
-
dependent feedback regulation of several ion channels [100]. CaM was shown 
to bind the CaM-binding regions in the COOH and NH2 of TRPV5 and 
TRPV6 as well as the transmembrane domain of TRPV6 in a Ca
2+
-dependent 
manner. Removal of the CaM-binding site in the COOH terminus of TRPV6 
resulted in a significant reduction of the slow component of channel 
inactivation, revealing a role of CaM in TRPV6 regulation [101]. These data 
demonstrated a regulatory role of CaM in TRPV6-mediated Ca
2+
 influx (fig.7). 
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80K-H 
In a microarray screen designed to identify proteins that respond similarly to 
vitamin D and/or altered dietary Ca
2+
 intake as TRPV5, Gkika et al. [102] 
identified 80K-H. 80K-H contains two putative EF-hand structures, a highly 
negatively charged glutamate stretch, which might be a Ca
2+
-interacting region, 
and a putative ER-targeting signal (HDEL). Using glutathione S-transferase 
(GST) pull-down assays and coimmunoprecipitations, a physical interaction 
between 80K-H and TRPV5 was demonstrated. Furthermore, both proteins 
colocalized in a subset of tubular segments in the kidney and show similar 
transcriptional regulation by vitamin D and dietary Ca
2+
 [102].  
80K-H directly binds Ca
2+
, which is abolished on inactivation of its two EF-
hand structures. Importantly, inactivation of the EFhand pair also reduces the 
TRPV5-mediated Ca
2+
 current and increased the TRPV5 sensitivity to 
intracellular Ca
2+,
 accelerating the feedback inhibition of the channel. 
Therefore, it is hypothesized that 80K-H acts a Ca
2+
 sensor to regulate TRPV5 
activity at the plasma membrane. 
 
 NHERF2  
The Na+/H+-exchanger regulating factors, NHERF1 or NHERF2, are PDZ 
domain containing proteins. PDZ motifs, which are also present in TRPV5 and 
TRPV6, are recognized by PDZ domains, which are modular protein 
interaction domains that play a role in protein targeting and protein complex 
assembly. It was demonstrated that TRPV5 activity increases on coexpression 
with the PDZ domain containing protein NHERF2 and serum- and 
glucocorticoid-indicible kinase 1 (SGK1) or SGK3 in X. laevis oocytes [103]. 
Deletion of the second but not the first PDZ domain in NHERF2 abrogates the 
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stimulating effect of SGK/NHERF2 on TRPV5 activity [104]. Using GST pull-
down and overlay assays, the specific interaction of NHERF2 with the last 
three amino acids (YHF) of the COOH terminus of TRPV5 was demonstrated. 
Furthermore, it was shown that TRPV6 does not bind NHERF2 [104]. These 
findings suggest that regulation of the epithelial Ca
2+
 channels by NHERF2-
SGK is limited to TRPV5 and operates via direct interaction with the channel 
(fig7). 
 
Rab11a 
Rab11a is a small GTPase  involved in trafficking via recycling endosomes 
[105]. It was recently identified as a novel TRPV5- and TRPV6-associated 
protein [106].  Although the role of Rab GTPases in protein trafficking has 
long been recognized, the underlying mechanism is far from understood. 
Rab11a colocalizes with TRPV5 and TRPV6 in Ca
2+
 -transporting epithelial 
cells of the kidney. Here, both TRPV5 and Rab11a are present in vesicular 
structures underlying 
the apical plasma membrane [107]. Using a combination of GST pull-down 
and coimmunoprecipitation assays, a direct interaction between Rab11a and the 
epithelial Ca
2+
 channels was demonstrated, hinting at a novel mechanism of 
Rab11amediated trafficking [107]. The binding of TRPV5/6 to Rab11a would 
provide the first evidence for an ion channel directly associating with a Rab 
GTPase. Furthermore, it was demonstrated that TRPV5 and TRPV6 
preferentially interact with Rab11a in its GDP-bound conformation. Expression 
of a mutant Rab11a protein, locked in the GDP-bound state, results in a marked 
decrease in channels at the cell surface, indicating a direct role of Rab11a in 
the trafficking of TRPV5/6 toward the plasma membrane. Therefore, it is likely 
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that TRPV5/6 channels, present on the (apical) plasma membrane, are being 
exchanged with TRPV5/6 channels from the intracellular (recycling) 
endosomes in a Rab11-dependent manner. 
 
 
Klotho 
The klotho gene is expressed predominantly in distal convoluted tubules in the 
kidney and choroid plexus in the brain. It is also expressed in several endocrine 
organs, including pituitary, parathyroid , pancreas, ovary, testis, and placenta. 
Despite the tissue-specific expression of the klotho gene, a defect in klotho 
expression causes systemic phenotypes, suggesting that Klotho may be 
involved in the regulation of an endocrine system. 
There are two forms of Klotho protein, membrane Klotho and secreted Klotho 
which exert distinct functions. Membrane Klotho forms a complex with 
fibroblast growth factor (FGF) receptors and functions as an obligate co-
receptor for FGF23, a bone-derived hormone that induces phosphate excretion 
into urine and control serum concetration of vitamin D [108, 109].  
Secreted Klotho functions as a humoral factor that regulates activity of 
multiple glycoproteins on the cell surface, including ion channels TRPV5 and 
growth factor receptors such as insulin/insulin-like growth factor-1 receptors. 
Secreted Klotho protein inhibits internalization of TRPV5 and increases the 
number of TRPV5 on the cell surface, thereby increasing TRPV5-mediated 
Ca2+ influx and renal Ca2+ reabsorption [110]. 
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BSPRY 
BSPRY (B-box and SPRY-domain containing protein) play a physiologic role 
as a negative direct modulator of the epithelial Ca
2+
 channel TRPV5. It was 
initially demonstrated the complete co-localization BSPRY with TRPV5 in 
Ca
2+
-transporting tubular segments of the kidney. Furthermore, stable 
expression of BSPRY significantly inhibited Ca
2+
  influx in confluent layers 
cells expressing TRPV5 and it is activity was inversely regulated by the 
calciotropic hormone vitamin D3 [111]. 
In a previous work in our laboratory , using a proteomic approach, we 
examined the global changes of protein profile between parathyroid adenomas 
and normal parathyroid tissues in an attempt to identify key proteins involved 
in neoplastic transformation [112]. Among signal transduction proteins, 
significant decrease of BSPRY expression in parathyroid adenomas was 
observed. 
 
 
Role of TRPV5/6 in Disease  
Alterations in TRPV5 and TRPV6 have severe implications for proper renal 
and intestinal Ca
2+
 (re)absorption and bone development. Therefore, a role for 
TRPV5 and TRPV6 has been considered in diverse Ca
2+
 -related disorders: 
 
Estrogens and Postmenopausal Osteoporosis 
The deleterious effects of estrogen deficiency after menopause lead t a negative 
Ca
2+
 balance associated with renal Ca
2+
 loss, intestinal Ca
2+
 malabsorption and 
postmenopausal osteoporosis, which can be corrected by estrogen replacement 
therapy [113, 114]. In addition, estrogen has been implicated in the protection 
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against Ca
2+
 nephrolithiasis via an increased reabsorption of Ca
2+
. In 
premenopausal women, kidney stone formation is less common than in age-
matched men, which is associated with a lower urinary Ca
2+
 excretion [115, 
116]. While estrogen has a stimulatory effect on the expression of active Ca
2+
 
transport proteins in both kidney and duodenum, including TRPV5 and 
TRPV6. Thus, the presence of estrogen may protect premenopausal women 
against Ca
2+
 nephrolithiasis by increasing TRPV5 expression and stimulating 
Ca
2+
 reabsorption. Conversely, decreased active Ca
2+
 transport through TRPV5 
and TRPV6 as a result of estrogen deficiency would be in line with increased 
Ca
2+
 wasting and Ca
2+
 malabsorption in postmenopausal women. 
 
 Vitamin D-Deficiency Rickets  
Vitamin D-deficiency rickets type I (VDDR-I) is an autosomal recessive 
disease characterized by low or undetectable levels of 1,25(OH)2D3 resulting in 
hypocalcemia, rickets, osteomalacia and growth retardation. The disease is 
caused by mutations in the 1αOHase gene . As previously mentioned, in 
1αOHase knockout mice a down-regulation of renal TRPV5 as well as 
intestinal TRPV6 expression was demonstrated, whereas supplementation with 
1,25(OH)2D3 or an enriched Ca
2+
 diet restored expression levels of these Ca
2+
 
transporters and serum Ca
2+
 concentrations [91-93]. These data suggest that  
TRPV5 and TRPV6 play a central role in the pathophysiology of vitamin D-
deficiency rickets and determine, at least in part, the clinical phenotype of 
VDDR-I. 
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PTH-Related Disorders 
There are several disorders with disturbed Ca
2+
 homeostasis, characterized by 
hypo- or hyperparathyriodism. Primary and secondary hyperparathyroidism are 
common disorders characterized by elevated PTH levels. Others involve 
inactivating mutations in the CaSR gene, resulting in familial hypocalciuric 
hypercalcemia or neonatal severe hyperparathyroidism [117], whereas 
autosomal dominant hypocalcemia is caused by activating mutations, resulting 
in hypoparathyroidism [118]. These PTH-related disorders are associated with 
hypo- or hypercalciuria, renal stone formation and bone abnormalities.  showed 
that PTH is positively involved in Ca
2+
 reabsorption through the upregulation 
of renal TRPV5, suggesting a possible role for the epithelial Ca
2+
 channels in 
the pathogenesis of PTH-related disorders. Furthermore, to minimize the effect 
of elevated PTH on bone and other tissues [119], vitamin D compounds have 
been widely used in the treatment of hyperparathyroidism. However, use of 
compounds such as 1,25(OH)2D3 has frequently been accompanied by the 
undesired side-effects of hypercalcemia and hyperphosphatemia, which 
increase the risk of soft tissue and vascular calcification. To avoid these 
negative effects, vitamin D analogues have been developed with the aim of 
suppressing PTH secretion with minimal calcemic action [120]. In addition to 
the effects of 1,25(OH)2D3 on Ca
2+
 (re)absorption, Hoenderop et al. showed 
that various vitamin D analogues all increased serum Ca
2+
 levels, although at 
different levels and time-scales, reflecting their individual pharmacokinetics 
[121]. 
Moreover, these vitamin D compounds differentially up-regulated the 
expression of TRPV5 and TRPV6 expression in kidney and intestine, by means 
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of variation in magnitude and duration of induction, which could explain the 
differences in calcemic activity of the vitamin D compounds [121].  
 
Cancer  
First evidence that TRP channels could be involved in the progression of 
certain types of cancer came from analysis of TRPM1, which gene expression 
is inversely correlated with the aggressiveness of malignant melanoma cells 
[122]. In addition, TRPV6 was shown to be strongly upregulated in carcinomas 
of various tissues, including prostate [123-125]. TRPV6 is highly expressed in 
prostate cancer cells compared with healthy prostate epithelia and TRPV6 
transcripts are abundantly expressed in lymph node metastasis of prostate 
origin [124, 126]. The appearance of TRPV6 correlates positively with the 
tumor grade and TRPV6 might, therefore, be a promising new marker for 
tumor progression and target for the development of drugs against prostate 
cancer. New evidences showed that decreased TRPV5 and TRPV6 expression 
was noted in renal cell carcinoma, which correlated with vitamin D receptor. 
This finding suggest that altered vitamin D receptor expression may be 
associated with renal cell carcinoma carcinogenesis via TRPV5 and TRPV6 
[127]. In addition, another study demonstrate the presence of TRPV5/V6 gene 
and protein expression and functional activity of TRPV5/V6 channels in 
human leukemia Jurkat T cells and in human blood lymphocytes (HBLs). 
Levels of TRPV5 and TRPV6 were significantly higher in malignant cells than 
in quiescent lymphocytes; furthermore, the TRPV6 upregulation correlated 
with cell-cycle progression in mitogenstimulated lymphocytes. These results 
open new perspectives on the role of TRPV6 channels in physiological 
responses of lymphocytes [128]. Other pieces of evidence demonstrate 
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TRPV5/6 upregulation and correlation with the advanced stages in colon, 
breast, thyroid, and ovarian carcinomas [129, 130]. 
 Anyway, little is known about their role in initiation or progression for most of 
cancers. The most probable mechanisms involve calcium signalling in the 
control of processes such as proliferation and apoptosis resistance. Further 
studies are needed to confirm whether these channels do really have an 
oncogenic potential or is just the last hope for transformed cells/tissues to stop 
cancer. 
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AIM 
 
TRPV5 and TRPV6, which are highly Ca
2+
-selective channels, play a pivotal 
role in the Ca
2+
-reabsorption in the kidney and intestine, respectively. The 
biological activity of TRPV5 and TRPV6 is coordinated and regulated in a 
different manner by various regulatory mechanisms, such as calciotropic 
hormones [1,25-dihydroxyvitamin D and parathyroid hormone (PTH)], pH, 
internal Ca
2+
 concentrations, and interaction with regulatory proteins. Besides 
the  maintenance of Ca
2+
 balance in health tissues, over-expression of 
TRPV5/TRPV6 mRNA and proteins were observed in advanced stages of 
prostate, colon, breast, thyroid and ovarian carcinomas and leukemia. 
However, little is known about their role in initiation or progression of tumors, 
although high expression of calcium channels is characteristic of cancer 
diseases through the control of processes, such as proliferation and apoptosis 
resistance  
As mentioned above, a concerted action of associated proteins in the regulation 
of the activity of TRPV5 and TRPV6 has been reported, in particular of 
inhibitor protein B-box and SPRY-domain containing protein (BSPRY) and 
RGS2 or positive regulator proteins as klotho and WNK3.  
In attempt to identify key proteins involved in neoplastic transformation, in a 
previous work, using a proteomic approach, we examined the global changes 
of protein profile between parathyroid adenomas and normal parathyroid 
tissues. Among signal transduction proteins, we observed a significant decrease 
of BSPRY expression in parathyroid adenomas.  
Taking into account the regulatory role of the BSPRY and the involvement in 
cell proliferation of TRPV5/ TRPV6, in this thesis we investigated the presence 
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of both channels in parathyroid adenoma and in parathyroid normal gland, 
either at mRNA or protein level. In the present work, for the first time, we 
provide evidence of the presence of TRPV5 and TRPV6 in human parathyroid 
glands and their protein over-expression in the parathyroid adenomas. This 
finding suggests a role of TRPV5/6 in parathyroid adenomas. Further studies 
are needed to confirm whether these channels do really have an oncogenic 
potential in parathyroid adenoms. 
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Materials and Methods 
 
Tissue specimens 
Ten parathyroid adenomas from patients with sporadic primary 
hyperparathyroidism (PHPT) and three normal parathyroid glands obtained 
from normocalcemic patients operated for nodular goiter were included in the 
study. For real time polymerase chain reaction (RT-PCR) experiments kidney 
and pancreas non-pathological specimens were used as internal controls. All 
tissues were immediately snap frozen in liquid nitrogen after surgery and 
stored at -80°C until use. Histopathological classification was according to the 
World Organization’s (WHO) guidelines [131]. 
 All patients gave their informed consent. The study was approved by the local 
Ethics Committee. 
 
Protein Extraction 
20-30  mg of tissue sample was suspended in 20 volumes of 10 mM Tris-HCl 
pH 7.4 containing a protease inhibitor cocktail (Sigma-Aldrich), and 
homogenized on ice with a potter homogenizer. The homogenate was 
centrifuged at 14000 g in an eppendorf centrifuge at 4°C for 20 min and the 
resulting supernatant was immediately stored at -80°C (S1) while the pellet 
(membrane fraction, P1) was resuspended in rehydration solution  (7M Urea, 
2M thiourea, 4% CHAPS, 60 mM DTT, 0.002% bromophenol blue) and 
incubated for 45 min under rotation at 4 °C. After incubation, the sample was 
centrifuged for 10 min at 14000 g to remove undissolved material. The protein 
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concentrations were measured with an RC-DC Protein Assay from Bio-Rad, 
using bovine serum albumin as a standard.  
 
 Western Blot Analysis 
Western blot analyses were carried out on protein extracts (S1 and P1).  
Aliquots of 60 µg of proteins were mixed with SDS sample buffer (Laemmli 
solution) and heated at 100°C for 5 min. Proteins were run on 8% SDS-PAGE 
gels, and transferred onto nitrocellulose membranes (0.2 µm) using 20mA for 
gel (Tetra cell apparatus, Biorad). Anti-TRPV5 - and anti-TRPV6- goat 
polyclonal antibodies (K-17 and L-15, respectively, Santa Cruz Biotechnology 
Inc., Santa Cruz, USA) were used at dilution of 1:200. After incubation with 
appropriate secondary antibody, immunoreactions were visualized using ECL 
detection system. The chemiluminescent images were acquired by LAS4010 
(GE Health Care Europe, Uppsala, Sweden). 
 
 Glycosylation Analysis 
Protein extracts (S1) expressing TRPV5 and TRPV6 were treated with 
peptide:N-glycosidase F (PNGaseF) (New England Biolabs Inc., MA, USA) 
according to the manufacturer’s instructions. An equal amount of proteins (75 
µg) was denaturated at 65°C for 10 min. After the addition of one-tenth volume 
of 10 X reaction buffer (0,5M Sodium Phosphate pH 7,5 and 10% NP-40) and 
3 µl (1,500 U) of PNGase F, or water (control reactions), samples were 
incubated at 37°C for 1-2 h  in a final reaction volume of 60 µl. Following the 
incubation, an equal volume of 2X Laemmli sample buffer was added to each 
reaction. The resultant samples were then analyzed by SDS-PAGE and western 
blot .  
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 Semi-quantitative and Quantitative Reverse Transcriptase PCR 
RNA extraction was performed using the PureLink RNA Mini Kit, according 
to the manufacturer's instructions (Invitrogen, Life Technologies Ltd, Paisley, 
UK). The concentration and purity of all RNA samples, eluted in a final 
volume of 30 μl RNase-Free water, were determined with a Nano-Drop® ND-
1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). One microgram of total RNA for each sample was reverse transcribed 
into cDNA in a 20 µl reaction volume using Superscript III reverse 
transcriptase (Invitrogen, Life Technologies Ltd, Paisley, UK). Qualitative 
PCR reactions were carried out in a MJ Research thermal cycler. TRPV5 and 
TRPV6 primers and PCR conditions were derived from Hoenderop et al [138]. 
cDNA yields for genes of interest were compared with glucose-6-phosphate 
dehydrogenase (G6PD) as a house-keeping control gene. Amplified TRPV5 
and TRPV6 cDNAs, were subsequently separated on 1.5% agarose gel, stained 
with ethidium bromide and photographed under UV illumination. The 
photographs were scanned on densitometry (Bio-Rad Laboratories, Hercules, 
CA, USA) and band intensity was evaluated using Quantity One software (Bio-
Rad Laboratories, Hercules, CA, USA). Each sample value was normalized for 
loading errors (dividing by intensity of G6PD); data were expressed as 
arbitrary units (A.U.) representing the ratio between the intensities of the band 
of interest and of the band corresponding to the control protein. PCR bands 
were cut from gel and directly sequenced in order to confirm the identities of 
the two transcripts.  
Quantitative gene expression study was performed by real time PCR using 
TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, 
USA). The primer/probe mixes which were used to amplify TRPV5 and 
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TRPV6 genes and the house-keeping gene glyceraldheide-3-phosphate 
dehydrogenase (GAPDH) were both purchased from Applied Biosystems 
(TaqMan® GeneExpression Assays-on-Demand). Briefly, PCR reaction was 
carried out in 96-well optical reaction plates using cDNA equivalent to 20 ng 
total RNA for each sample (parathyroid adenomas and a pool of 3 normal 
parathyroid glands) in a volume of 25 µl using the TaqMan Universal PCR 
Master Mix (Applied Biosystems, Life Technologies Ltd, Paisley, UK) 
according to the manufacturer's instructions. PCR was run on the ABI Prism 
7700 Sequence Detector (Applied Biosystems, Life Technologies Ltd, Paisley, 
UK).  The analysis of relative gene expression data was performed using the 
ΔΔCT method with the housekeeping gene GAPDH as an endogenous 
control/reference assay.  The results were expressed as the amount of target 
gene normalized to the endogenous reference and relative to a calibrator (pool 
of normal parathyroid tissues).  
 
Cell Culture  
Specimens of three different adenoma parathyroid glands from patients with 
sporadic PHPT were used for cell culture experiments. Primary cell cultures 
were prepared directly after parathyroidectomy (PTx) according to published 
procedures [132]. Briefly, the excised parathyroid glands were immediately 
suspended in sterile medium after PTx and minced with scalpels after the 
removal of visible fat and connective tissue, and cell suspensions were 
prepared by incubation in 2mg/ml collagenase dissolved in DMEN-F12 
medium, for 2h at 37 °C. Then, the cells were mechanically dispersed, filtered 
through sterile gauzes and centrifuged. Washed pellets were suspended in 
DMEN-F12 medium  added with 10% fetal bovine serum. The cells were 
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counted and plated at a density of 5x10
5
 cells/well onto the BioCoat Cellware 8 
wells chamber slide pre-coated with Poly-Lysine (BD Biosciences), grown at 
37 °C in 5% CO2  humidified atmosphere for 24, 48 and 72 h. 
 
 
 Immunocytochemistry (ICCH) 
Primary human parathyroid cells incubated for 24, 48 and 72 hours were fixed 
in 2% paraformaldheyde in 0.1M phosphate buffer, washed three times in 
phosphate buffer saline (PBS), rinsed and blocked for 45 min in a solution of 
0.1% Triton-X 100, 1% bovine serum albumin (BSA) in PBS. After washing, 
the cells were incubated with goat polyclonal anti-TRPV5 or anti-TRPV6 
primary antibodies (1:250, Santa Cruz Biotechnology) or mouse monoclonal 
anti-CASR primary antibody (1:500, Affinity BioReagents, Suite, CO, USA) 
with 0.03% Triton-X 100 and 1% BSA. The co-localization was obtained by 
incubation of anti-TRPV5 and anti-CASR or anti-TRPV6 and anti-CASR. The 
primary antibodies were incubated overnight at 4°C. After the washing, in 
order to visualize single staining, the cells were incubated with donkey anti-
goat antibody (1:400, Sigma Aldrich, St Louis, MO, USA) or with goat anti-
mouse (1:400, Invitrogen Life Technologies Ltd, Paisley, UK) conjugated with 
Alexa Fluor 488; furthermore, in order to visualize the co-localization, the cells 
were incubated with donkey anti-goat conjugated with Alexa Fluor 488 (1:400, 
Sigma Aldrich) and with donkey anti-rabbit conjugated with Rhodamin-RedX 
(1:400, Jackson ImmunoResearch Laboratories). The secondary antibodies 
were incubated for 2 hours at room temperature and then the slides were 
covered with Vectashield (Vector Laboratories, Burlingame, CA, USA). Nuclei 
were stained by the red fluorescent nuclear propidium.  Confocal images were 
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obtained with a Leica TCS-SP5 confocal microscope, using a 40x oil objective 
with 1.45 NA and a recommended pinhole size of less than 1.0 micrometer.  
The scanning fields were 250 x 250 microns in size and consisted of 4 
consecutive acquisitions along the z axis, totally encompassing a thickness of 4 
micrometers. Saved files were focus extended images obtained automatically 
by superposition of the 4 focal planes. The images were processed with 
PhotoshopCS3 software. 
 
 Statistical Analysis 
The antigen-specific bands were quantified using the ImageQuant-L (GE 
Health Care Europe Uppsala, Sweden). The significance of the differences (p-
value≤0.05) between adenoma and normal samples was calculated by the 
Student’s t-test.  All the experiments were performed in duplicate.   
In the gene expression experiments, the fold of difference between normal and 
adenoma parathyroid samples was calculated as 2
−ΔΔCt, where ΔΔCt = (ΔCt 
sample − ΔCt calibrator) and ΔCt = (Ct value of TRPV5 or TRPV6 − Ct value 
of GAPDH). The average Ct value of a pool of normal parathyroids was used 
as the calibrator in the analysis. Each experiment was performed in duplicate. 
The Student’s t-test was used to test the significance of differential mRNA 
expression between samples, while  the risk level (p) was set at *<0.05, 
**<0.01, ***<0.001. 
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Results 
 
Western Blot 
Western blot analysis was performed to determine the presence of TRPV5 and 
TRPV6 proteins in parathyroid  tissues. The search was carried out both in 
soluble fraction (S1) and membrane extracts (P1).  
 
Figure 8. Representative immunoblot of protein membrane extracts (P1) from 
normal and adenoma parathyroid samples. (A) SDS gels were run using 8% 
resolving capacity. Sixty micrograms of total proteins were loaded for each 
sample. Proteins were transferred onto nitrocellulose membranes and 
incubated with specific antibodies against the target proteins (TRPV5 and 
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TRPV6). (B) Densitometry of the blots is shown for 80-85 kDa bands. Bar 
graphs represented the mean ± SD of the normal (n=3) and adenoma (n=10) 
P1 samples. Statistically significant differences were determined by Student t-
test and p values calculated (***p<0.001). 
 
 
 
Figure 9. Representative immunoblot of protein membrane extracts (S1) from 
normal and adenoma parathyroid samples before and after PNGaseF 
treatment. (A) Aliquots of normal and adenoma parathyroid S1 samples were 
denaturated at 65 °C for 10 minutes and incubated with (+) or without (-) 
PNGase F (1,500 U) at 37 °C for 1-2 h  in a final reaction volume of 60 µl.  
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SDS gels were run using 8% resolving capacity. Twenty-five micrograms of 
total proteins were loaded for each sample. Proteins were transferred onto 
nitrocellulose membranes and incubated with specific antibodies against the 
target proteins (TRPV5 and TRPV6). (B) Densitometry of the blots is shown 
for 80-85 kDa bands. Bar graphs represented the mean ± SD of the normal 
(n=2) and adenoma (n=2) S1 samples. A reduction of intensities of main 80-85 
kDa bands of about 40% was detected in all S1 samples after PNGaseF 
treatment both in normal and adenoma samples. 
 
Figures 8A and 9A show an example of western blots of P1 and S1 samples, 
respectively,  for both TRPV5 and TRPV6. The prominent immunoreactive 
band was detected at about 80-85 kDa for both TRPV proteins. Additional 
weaker bands at about 135, 110, 47-60 and 30 kDa were observed mainly in S1 
(Fig.8A) with respect to P1 samples (Fig.9A) with different patterns between 
TRPV5 and TRPV6. Comparing adenoma and normal samples, a significant 
difference of expression was detected only for 80-85 kDa band both in P1 
(p<0.001) and S1 (p<0.05) extracts.  Figures 8B and 9B show the derived bar 
graphs for prominent band. Both vanilloid channel proteins showed a greater 
expression in adenoma compared to normal samples, ranging from 2.7 to 5 fold  
and from 25 to 29 fold in S1 and P1 samples, respectively.  In addition, a 40% 
reduction of intensity of the main band was detected in all S1 samples after 
PNGaseF treatment, which was able to remove all the N-linked 
oligosaccharides (Figures 9A and 9B). After deglycosydase treatment, a 50-
60% reduction  was also observed for 135 kDa band, while other minor bands 
were weakly reduced (Figures 9A and 9B), suggesting a diffuse glycosylation 
pattern of both channels. The immunoreactivity patterns of vanilloid channels 
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were also confirmed with various commercial  antibodies directed to different 
regions of TRPV5 and TRPV6. 
 
   
 Semi-Quantitative RT-PCR 
Reverse transcriptase PCR analysis showed the presence of both TPRV5 and 
TPRV6 transcripts in parathyroid adenomas. Direct sequencing of the bands 
relative to TRPV5 and TRPV6 transcripts confirmed their identity (data not 
shown). The results of a representative experiment are shown in Fig. 10A. In 
the pancreas, the ratio of TRPV5/TRPV6 transcripts confirmed a greater 
expression of TPRV6 compared to TRPV5. Densitometric data of bands 
obtained by two independent experiments revealed a statistically significant 
relative abundance of TRPV6 (p<0.05) compared to TRPV5 transcripts in 
parathyroid adenomas (Fig. 10B).  
 
Quantitative real-time PCR 
 The comparative real-time PCR showed that parathyroid adenomas had a 
lower level of expression with respect to the pool of normal parathyroid glands 
(p<0.001), both for TRPV5 and TRPV6 genes, which was on average 16 and 4 
fold less, respectively (Fig. 10C). In the kidney, the expression of  TRPV5 
transcripts was statistically higher compared to normal parathyroid tissues 
(p<0.05). On the other hand, in the pancreas the expression of transcripts was 
statistically lower for TPRV5 (p<0.05) and higher for TPRV6 (p<0.01) 
compared to normal parathyroid (Fig. 10C).  
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Figure 10. Semi-quantitative and quantitative reverse transcriptase PCR for 
TRPV5 and TRPV6 genes. (A) The PCR products of reverse trascripted 
mRNAs were separated by agarose gel electrophoresis and detected by 
ethidium bromide staining. The arrows shows the amplified TRPV5 and 
TRPV6 cDNAs with the 301 and 312 bp expected size, respectively, in two 
different parathyroid adenomas (lanes 1, 2) and in the human non-pathological 
pancreas used as a positive control (lane 3). G6PD was used as loading control. 
(B) Bar graph representing quantified densitometry of data showed in (A). 
Each bar represents mean values with positive error bars (SD) of two 
independent experiments. Each sample value was normalized dividing by the 
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intensity of G6PD and the obtained data were expressed as arbitrary units. The 
graph shows the relative abundance of TRPV6 transcripts either in the pancreas 
or in parathyroid adenomas (PA) compared to TRPV5. (C) Bar graph 
representing real time PCR results. The figure shows the mRNA expression 
fold change of the two target genes (TRPV5 and  TRPV6) using the 2ΔΔCT 
method relative to the internal control gene (GAPDH) in different tissue 
specimens. The fold difference was calculated as 2−ΔΔCt, where ΔΔCt = (ΔCt 
sample − ΔCt calibrator) and ΔCt = (Ct value of TRPV5 or TRPV6 − Ct value 
of GAPDH). The average Ct value of a pool of 3 normal parathyroids (PN) was 
used as the calibrator in the analysis. Genes up or down-regulation were 
expressed as mean ± SD of TRPV5 or TRPV6/GAPDH ratio of three 
independent experiments using a non-pathological kidney and a non-
pathological pancreas tissue and a total of eight different parathyroid adenomas 
(PA) analyzed in duplicate. Statistical significance was determined by 
Student’s t-test where * p< 0.05, ** p < 0.01 and ***p<0,001. 
 
Immunocytochemistry  
Primary human parathyroid cells maintained in culture expressed both channels 
starting from 24 hours. Figure 11 shows that the immunoreactivity of TRPV5 
and TRPV6 (green) is localized not only on plasma membranes but also in the 
cytosol and around nuclei (red).  
The expression of TRPV5, TRPV6 and CASR as a function of the time of cells 
incubation, is shown in Figure 12, where specific markers were employed. Of 
note, TRPV5-6 expression progressively decreases from 24 to 72 hours, 
whereas CASR expression increases over time, reaching the highest expression 
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after 72 hours (panel A). Panel B shows the co-localization of TRPV5, TRPV6 
(green) and CASR (red) in the majority of parathyroid cells.  
 
 
 
 
Fig. 11. Confocal images of primary human parathyroid cells  staining with 
antibody anti-TRPV5 and 6 (green). Nuclei were stained with propidium (red). 
Scale bars: 10 μ 
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Fig. 12. Confocal images of primary human parathyroid cells maintained at 
different times of incubation. Panel A shows the expression  of TRPV5, TRPV6 
and CASR (green) respectively  at 24, 48 and 72 hr. Panel B shows the co-
localization between TRPV5, TRPV6 (green) and CASR (red).  Scale bars: 10 
μm. 
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Discussion 
TRPV5 and TRPV6 are two high selective Ca
2+
 channels predominantly 
localized in epithelial tissues and presumably involved in transcellular calcium 
transport [85,86,87]. Their main physiological  functions occur at kidney and 
intestine level where these channels are prime targets of  calciotropic 
hormones, such as PTH and 1,25-dihydroxyvitamin D, in the control of Ca
2+
 
reabsorption from pro-urine (TRPV5) and intestine Ca
2+
 uptake (TRPV6). 
These physiological functions are the result of a concerted action of associated 
proteins which, in addition to Ca
2+
 itself, play key roles in the positive (i.e 
klotho, WNK3) and negative (i.e BSPRY) regulation of TRPV5 and TRPV6 
channels [114-117]. In a previous work we demonstrated the presence of 
BSPRY protein in human parathyroid glands, showing a significant down-
regulation of BSPRY protein in adenoma with respect to normal glands [116]. 
The identification of a negative modulator of TRPV5 and TRPV6 channels led 
us to investigate the presence of these channels in human parathyroid glands. 
Up to date, the presence of TRPV5 and TRPV6 has been demonstrated in 
various pathological and non-pathological human tissues and cell lines [134]. 
The expression of CAT-L, a human homologue of rat TRPV6, has previously 
been investigated by Northern blot analysis in 2 healthy parathyroid tissues by 
Wissenbach et al, with negative results [128]. In this work, the presence of 
TRPV5 and TRPV6  proteins and of their mRNAs was studied using human 
parathyroid tissues, while their cellular localization and time expression was 
evaluated by immunocytochemical assay on primary human adenoma 
parathyroid cells. 
Reverse transcriptase PCR, western blot, and immunocytochemistry assays all 
indicate, for the very first time, that TRPV5 and TRPV6 channels are 
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expressed in both human normal and pathological parathyroid glands. 
Quantitative evaluation of western blotting data showed an over-expression of 
both channels in adenoma with respect to normal parathyroid tissues, either for 
membrane or for soluble fraction preparations with different ratio. High levels 
of these proteins in the soluble fraction suggest an active recycle of these 
channels in parathyroid glands, as already described [102-110]. Moreover, 
immunocytochemical results confirmed that they localize not only in the 
plasma membrane, but also in the cytosol and around the nuclei.   
As mentioned above, it has been documented that the number of TRPV5 and 
TRPV6 on the plasma membrane is determined by counterbalance between 
insertion by forward trafficking from Golgi and removal by endocytosis to 
endosomes. This regulation appears operated by glycosydase enzymes, such as 
klotho and leads to accumulation of channels on the plasma membrane and 
consequently to an increase in calcium influx [107-110]. Indeed, our PNGaseF 
experiments indicated that the cores of both channels were glycosylated with 
apparent molecular weight of 83 kDa. Further investigations are needed to 
explain the mechanisms regulating the glycosylation and deglycosylation 
processes of TRPV5 and TRPV6 channels in parathyroid glands and their 
possible involvement in the tumorigenesis. On the other hand, various reports 
suggested that TRPV5 and TRPV6 channels may contribute to cell 
proliferation and malignant growth [126-130]. Specifically, TRPV6 up-
regulation was described in prostate cancer and other cancer of epithelial 
origin, such as breast, colon, thyroid and ovarian carcinomas [129]. The link 
between tumour growth and protein over-expression of TRPV6 may involve 
the potentiation of calcium-dependent cell proliferation and the inhibition of 
apoptosis [123-130]. In parathyroid adenomas the neoplastic proliferation and 
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the hormonal dysregulation, i.e. increased secretion of PTH, which in 
consequence leads to hypercalcemia, are tightly linked [126]. A shift in 
calcium-sensitive parathyroid hormonal regulation could be the cause or the 
result of abnormal parathyroid proliferation. Whether the TRPV5 and TRPV6 
over-expression in this context could directly contribute to tumorigenesis or 
represent a secondary event of hypercalcemia needs to be further elucidated. 
Generally, mRNA and proteins of TRPV5 and TRPV6 are up-regulated in 
tumor tissues and cell lines when compared with normal and correlate with 
tumour progression [129, 133, 134]. Similarly, we observed an increase of 
protein expression of both channels in parathyroid adenomas in comparison 
with normal glands, but opposite results were obtained for mRNA quantitative 
expression. A decrease of TRPV5 and TRPV6 mRNAs, strictly correlated with 
vitamin D receptor (VDR) expression, was observed in renal cell carcinoma by 
Wu and coworkers [127]. Indeed, a down-regulation of VDR mRNA is well 
documented in parathyroid adenomas [31]. Nevertheless, the relationship 
between the expression of mRNA and its protein is not well characterized in 
human cancer. In fact, it has been described that discordant or opposite 
correlations can be observed, especially for proteins which present post-
translational modifications leading to various isoforms and for less abundant 
proteins [135]. This concept might explain the discordance we observed 
between mRNA and protein expression even if further investigations are 
needed.     
In conclusion, our results show the presence of TRPV5 and TRPV6 channels in 
both normal parathyroid glands and parathyroid adenomas. Both channels were 
over-expressed in parathyroid adenomas. Our findings likely suggest that 
altered TRPV5 and TRPV6 expression may be associated with parathyroid 
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adenoma. Consequently, further studies are needed to identify the mechanisms 
regulating TRPV5 and TRPV6 expression in parathyroid glands and their 
relation with the cell calcium signaling pathway and the pathological processes 
of these glands. 
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